Next Article in Journal
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Next Article in Special Issue
From Jekyll to Hyde: The Yeast–Hyphal Transition of Candida albicans
Previous Article in Journal
Profiling of Intestinal Microbiota in Patients Infected with Respiratory Influenza A and B Viruses
Previous Article in Special Issue
The Synthesis and Evaluation of Multivalent Glycopeptoids as Inhibitors of the Adhesion of Candida albicans
Article

Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1

by 1,2,†, 3,†, 1,* and 3,*
1
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
2
Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, WI 53226, USA
3
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally.
Academic Editor: Jonathan Richardson
Pathogens 2021, 10(6), 762; https://doi.org/10.3390/pathogens10060762
Received: 11 May 2021 / Revised: 8 June 2021 / Accepted: 12 June 2021 / Published: 17 June 2021
(This article belongs to the Special Issue Candida albicans: A Major Fungal Pathogen of Humans)
Candida species cause serious infections requiring prolonged and sometimes toxic therapy. Antimicrobial proteins, such as chemokines, hold great interest as potential additions to the small number of available antifungal drugs. Metamorphic proteins reversibly switch between multiple different folded structures. XCL1 is a metamorphic, antimicrobial chemokine that interconverts between the conserved chemokine fold (an α–β monomer) and an alternate fold (an all-β dimer). Previous work has shown that human XCL1 kills C. albicans but has not assessed whether one or both XCL1 folds perform this activity. Here, we use structurally locked engineered XCL1 variants and Candida killing assays, adenylate kinase release assays, and propidium iodide uptake assays to demonstrate that both XCL1 folds kill Candida, but they do so via different mechanisms. Our results suggest that the alternate fold kills via membrane disruption, consistent with previous work, and the chemokine fold does not. XCL1 fold-switching thus provides a mechanism to regulate the XCL1 mode of antifungal killing, which could protect surrounding tissue from damage associated with fungal membrane disruption and could allow XCL1 to overcome candidal resistance by switching folds. This work provides inspiration for the future design of switchable, multifunctional antifungal therapeutics. View Full-Text
Keywords: Candida; C. albicans; XCL1; metamorphic protein; fold-switching protein; antifungal peptide Candida; C. albicans; XCL1; metamorphic protein; fold-switching protein; antifungal peptide
Show Figures

Figure 1

MDPI and ACS Style

Dishman, A.F.; He, J.; Volkman, B.F.; Huppler, A.R. Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1. Pathogens 2021, 10, 762. https://doi.org/10.3390/pathogens10060762

AMA Style

Dishman AF, He J, Volkman BF, Huppler AR. Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1. Pathogens. 2021; 10(6):762. https://doi.org/10.3390/pathogens10060762

Chicago/Turabian Style

Dishman, Acacia F., Jie He, Brian F. Volkman, and Anna R. Huppler. 2021. "Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1" Pathogens 10, no. 6: 762. https://doi.org/10.3390/pathogens10060762

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop